Floatz Rating
C39/100
Confidence
Indicative
Sponsor
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Modality
Cell therapy
Development Phase
Early Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
24Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07656103CT.gov QH101 Cell Injection in Patients With Brain, Brain (Spinal) Meninges, and Spinal Cord Metastatic Malignant Solid Tumors | — | Not Yet Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Neoplastic Meningitis
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| qh101 cell (this asset) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Early P1 | C · 39 |
| Cytarabine | Fudan University | P4 | BBB |
| Dexasone | Shanghai Cancer Hospital, China | P2 | B |
| Durvalumab | Hui Bu | P4 | B |
| Lorlatinib | Guangdong Association of Clinical Trials | P4 | B |
| Etoposide | Guangzhou Medical University | P2 | B |
| Methotrexate | The First Affiliated Hospital with Nanjing Medical University | P4 | B |
| Cis-Diamminedichloroplatinum Ii | Guangzhou Medical University | P2 | B |
| Cyclophosphamide | Medical College of Wisconsin | P2 | B |
+39 more in the Neoplastic Meningitis cohort
Other indications for qh101 cell
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Metastatic Malignant Neoplasm In The Brain | — | Early P1 | C · 39 |
| Metastatic Malignant Neoplasm In The Spinal Cord | — | Early P1 | C · 39 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. qh101 cell in Neoplastic Meningitis. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/qh101-cell-neoplastic-meningitis
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →